- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01214668
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
A Phase 1b, Multicenter, Dose-Escalation Study of LY573636-sodium in Combination With Liposomal Doxorubicin in Patients With Advanced Solid Tumors
The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as LY573636) that can be administered safely in combination with liposomal doxorubicin in patients with advanced cancer who have failed a prior treatment.
The study consists of a dose escalation phase to the maximum tolerated dose (MTD) and a dose confirmation phase in patients with platinum resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have never been treated with doxorubicin.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85258
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
California
-
Encinitas, California, Estados Unidos, 92024
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38119
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- You must have a histologically confirmed solid malignancy that is unresectable and/or metastatic which has progressed after receiving standard approved chemotherapy
- You must have a solid malignancy for which an anthracycline-based regimen is felt to be a reasonable treatment option
- You must have measurable disease or non-measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)
- You must have a serum albumin level greater than or equal to 3.0 grams/deciliter (g/dL) (30 g/L)
- You must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- You must have tumor progression after receiving standard/approved chemotherapy
- You must be reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures
- Women must be sterile, post-menopausal or on a contraception and men must be sterile or on contraception
- Your test results assessing the function of your blood, kidneys, liver, and heart are satisfactory
- Ovarian patients in the confirmation phase must have failed to achieve at least a partial response to a first-line platinum-based therapy (platinum-refractory) or have progression in less than 6 months after a response to a first-line platinum-based therapy (platinum-resistant)
- Ovarian patients in the confirmation phase must have measurable disease by RECIST
- Ovarian patients in the confirmation phase must be liposomal doxorubicin or doxorubicin naive and not amendable to curative therapy
Exclusion Criteria:
- You cannot have received other investigational drugs within the last 28 days
- You cannot have other on-going serious illnesses including active bacterial, fugal, or viral infections
- You cannot have current hematologic malignancies, acute or chronic leukemia, or brain metastasis
- You cannot currently be receiving warfarin (Coumadin®) therapy
- You cannot have known positive test results in human immunodeficiency, hepatitis B surface antigen or hepatitis C antibodies
- You cannot have a history of cardiac disease or clinical evidence of congestive heart failure
- Ovarian patients in the confirmation phase who have received 2 or more cytotoxic regimens for platinum-resistant disease
- You cannot currently be receiving amiodarone, quinidine, propofol, and clozapine
- If you are taking esomeprazole or pantoprazole you must be able to stop taking this medication within 72 hours before and after LY573636 administration
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: LY573636 + Liposomal Doxorubicin
|
Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met.
Otros nombres:
40 mg/m² on Day 1, given intravenously of each 28-day cycle Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Recommended Phase 2 Dose
Periodo de tiempo: Predose up to 28 days postdose in Cycle 1
|
Recommended Phase 2 dose was determined by maximum tolerated dose (MTD), which is corrected for the participant's predose albumin to identify the albumin-corrected exposure range of LY 573636 when combined with liposomal doxorubicin.
MTD is the highest dose with <33% of participants having a dose-limiting toxicity (DLT) in the first 28-day cycle of treatment.
DLT is an adverse event (AE) that is likely related to the study drug or combination and fulfills any 1 of the following: Common Terminology Criteria for AE (CTCAE, Version 3.0) Grade (Gr) 4 hematologic toxicity; Gr 3 nonhematologic toxicity (excluding controllable nausea/vomiting or diarrhea and alopecia); Gr 3 electrolyte toxicity that is not resolved with standard treatments.
Those who enter the study with Gr 2 hepatic enzyme abnormalities, DLT for an isolated Gr 3 hepatic enzyme abnormality is determined by investigators; a DLT can be declared if a participant experiences increasing toxicity during treatment.
|
Predose up to 28 days postdose in Cycle 1
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Clinically Significant Events
Periodo de tiempo: Baseline to study completion up to 18.49 months
|
Clinically significant events are defined as serious adverse events (SAEs), regardless of causality, during the study including the 30-day follow-up period.
A summary of SAEs and other nonserious adverse events is located in the Reported Adverse Event section.
Death due to progressive disease was not considered as an SAE.
|
Baseline to study completion up to 18.49 months
|
Pharmacokinetics: Maximum Concentration (Cmax) of LY573636
Periodo de tiempo: Predose, 30 minutes (min), 2 hours (h), 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
Predose, 30 minutes (min), 2 hours (h), 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
|
Number of Participants With Tumor Response
Periodo de tiempo: Baseline to measured progressive disease up to 4.7 months
|
Number of participants with tumor response = number of participants with complete response (CR) + number of participants with partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines.
CR is the disappearance of all target and non-target lesions; PR is a ≥30% decrease in the sum of longest diameter of target lesions.
|
Baseline to measured progressive disease up to 4.7 months
|
Pharmacokinetics: Area Under the Curve of LY573636 Above the Albumin Corrected Threshold (AUCalb)
Periodo de tiempo: Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
LY573636 has been found to be highly bound to albumin.
AUCalb is a surrogate measure of exposure to unbound (free) LY573636.
|
Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
Otras medidas de resultado
Medida de resultado |
Periodo de tiempo |
---|---|
Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment
Periodo de tiempo: From date of randomization until up to 30 days post study treatment discontinuation, assessed up to 4.7 months
|
From date of randomization until up to 30 days post study treatment discontinuation, assessed up to 4.7 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Call 1-877-CTLILLY (1-877-285-4559) or 317-651-4559 Mon. - Fri. 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 12887
- H8K-MC-JZAN (Otro identificador: Eli Lilly and Company)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Tumores sólidos
-
AstraZenecaReclutamientoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, cáncer gástrico, de mama y de ovarioEspaña, Estados Unidos, Bélgica, Reino Unido, Francia, Hungría, Canadá, Corea, república de, Australia
Ensayos clínicos sobre LY573636-sodium
-
Eli Lilly and CompanyTerminadoLeucemia mieloide aguda | Trombocitemia esencialEstados Unidos
-
Eli Lilly and CompanyTerminadoCáncer de ovarios | Cáncer de trompa de Falopio | Cáncer peritoneal primarioItalia, Estados Unidos, Federación Rusa
-
Eli Lilly and CompanyTerminadoMelanoma metastásicoAustralia, Estados Unidos
-
Eli Lilly and CompanyTerminadoSarcoma De Tejido BlandoEstados Unidos, España, Argentina
-
Eli Lilly and CompanyTerminadoCáncer de mamaEstados Unidos
-
Eli Lilly and CompanyTerminadoLinfoma | Cáncer avanzadoReino Unido
-
Eli Lilly and CompanyTerminadoCáncer de pulmón de células no pequeñasAlemania, Italia
-
National Taiwan University HospitalTCM Biotech International CorporationReclutamientoCistitis por radiaciónTaiwán
-
Paradigm Biopharmaceuticals USA (INC)Activo, no reclutandoArtrosis, RodillaAustralia, Estados Unidos
-
Cairo UniversityReclutamientoComplicaciones maternas después de la anticoagulación oral cuando se inicia temprano y tarde después de la cesárea realizada para pacientes con prótesis de válvula cardíaca mecánicaEgipto